

INSTITUTIONAL ETHICS COMMITTEE (IEC)

Seth GS Medical College and KEM Hospital

Established in 1986

IEC-I Re-registration No. ECR/229/Inst./MH/2013/RR-16, IEC-II registration No.

ECR/417/Inst./MH/2013 Issued under rule 122DD of Drugs & Cosmetic rule 1945.

Recognized by:

The Strategic Initiative for Developing Capacity in Ethical Review (SIDCER),
Forum for Ethical Review Committees in Asia and the Western Pacific Region (FERCAP)
for its compliance with international and local standards in ethical review.



Annexure 2

AX 02/SOP 11-B/V5

Serious Adverse Event analysis Report

(For SAE at the site)

Sr. No.	Details		
1.	Country (Name of the country should be specified)		
2.	SAE report of death or other than death, Please tick (✓)	Death ☐ Yes / No	Other than Death ☐ Page No.
3.	In case of Serious Adverse Event(SAE), please specify if there is any injury to the participant (Please specify Yes/No) in the box		
4.	Protocol Title		
5.	Protocol Study No./ ID /Code		
6.	Copy of Clinical Trial permission obtained from CDSCO		
7.	CTRI Registration No. (Mandatory for Clinical Trial Permitted after 15/06/09)		
8.	Sponsor(Address with contact no and Email)		
9.	CRO (Address with contact no and Email)		
10.	Initial / Follow-up (FU)		
11.	In case of follow-up: Date & Diary no of initial or recently submitted report information		
12.	Patient Details		
a)	Initials & other relevant identifier (hospital/OPD record number etc.)		
b)	Gender		
c)	Age and/or date of birth		
d)	Weight		
e)	Height		
13.	Suspected Drug(s)		
a)	Generic name of the drug.		
b)	Indication(s) for which suspect drug was prescribed or tested.		
c)	Dosage form and strength.		
d)	Daily dose and regimen (specify units - e.g., mg, ml,		

INSTITUTIONAL ETHICS COMMITTEE (IEC)

Seth GS Medical College and KEM Hospital

Established in 1986

IEC-I Re-registration No. ECR/229/Inst./MH/2013/RR-16, IEC-II registration No.

ECR/417/Inst./MH/2013 Issued under rule 122DD of Drugs & Cosmetic rule 1945.

Recognized by:

The Strategic Initiative for Developing Capacity in Ethical Review (SIDCER),
Forum for Ethical Review Committees in Asia and the Western Pacific Region (FERCAP)
for its compliance with international and local standards in ethical review.



	mg/kg).		
e)	Route of administration.		
f)	Starting date and time of day.		
g)	Stopping date and time, or duration of treatment		
14.	Other Treatment(s)		
	Provide the same information for concomitant drugs (including non prescription/OTC Drugs) and non-drug therapies, as for the suspected drug(s).		
15.	Details of the events		
a)	Full description of event (s) including body site and severity, as well as the criterion (or criteria) for regarding the report as serious. In addition to a description of the reported signs and symptoms, whenever possible, describe a specific diagnosis for the reaction.		
b)	Start date (and time) of onset of reaction.		
c)	Stop date (and time) or duration of reaction.		
d)	Dechallenge and rechallenge information.		
e)	Setting (e.g., hospital, out-patient clinic, home, nursing home).		
16.	Outcome		
a)	Information on recovery and any sequelae; results of specific tests and/or treatment that may have been conducted.		
b)	For a fatal outcome, cause of death and a comment on its possible relationship to the suspected reaction; any post-mortem findings.		
c)	Other information: anything relevant to facilitate assessment of the case, such as medical history including allergy, drug or alcohol abuse; family history; findings from special investigations etc.		
17.	Details about the Investigator		
a)	CT Site Number, if any		
b)	Name		
c)	Address		
d)	Telephone/Mobile Number & Email		
e)	Profession (speciality)		
f)	Date of reporting the event to Licensing Authority:		
g)	Date of reporting the event to Ethics Committee		

INSTITUTIONAL ETHICS COMMITTEE (IEC)

Seth GS Medical College and KEM Hospital

Established in 1986

IEC-I Re-registration No. ECR/229/Inst./MH/2013/RR-16, IEC-II registration No. ECR/417/Inst./MH/2013 Issued under rule 122DD of Drugs & Cosmetic rule 1945.

Recognized by:

The Strategic Initiative for Developing Capacity in Ethical Review (SIDCER),
Forum for Ethical Review Committees in Asia and the Western Pacific Region (FERCAP)
for its compliance with international and local standards in ethical review.



	overseeing the site:		
h)	Signature of the Investigator		
18.	Details about the Ethics Committee		
a)	Name & Address		
b)	Name of Chairman & Address		
c)	Telephone/Mobile Number		
d)	Email		
19.	Adverse Event Term / Details of SAE		
20.	Causality Assessment (Related/Unrelated) by Investigator.		
21.	Causality Assessment (Related/Unrelated) by Sponsor/CRO		
22.	Details of compensation provided for injury or death. In case no compensation has been paid, reason for the same :		
23. a)	Duly filled SAE Form as per Appendix XI of Schedule Y		
b)	Laboratory investigations report /Discharge summary (if available and applicable)		
c)	Post-mortem report (if applicable)/ Any additional documents)		
Details of payment for medical management of SAE? (please give information who paid how much was paid, to whom, with evidence of the same)			
What is the investigator's assessment for the amount of compensation to be paid?			
What is the sponsor's assessment for the amount of compensation to be paid?			
Has the participant made a claim? Yes No			
If yes, for how much amount _____			
If no, please ensure that the participant / nominee have been made aware of his/her' rights regarding compensation. Please submit documentation regarding the same			

INSTITUTIONAL ETHICS COMMITTEE (IEC)

Seth GS Medical College and KEM Hospital

Established in 1986

IEC-I Re-registration No. ECR/229/Inst./MH/2013/RR-16, IEC-II registration No. ECR/417/Inst./MH/2013 Issued under rule 122DD of Drugs & Cosmetic rule 1945.

Recognized by:

The Strategic Initiative for Developing Capacity in Ethical Review (SIDCER),
Forum for Ethical Review Committees in Asia and the Western Pacific Region (FERCAP)
for its compliance with international and local standards in ethical review.



Signature of the Principal Investigator : Date: _____
For IEC office use only Verified by: Name: _____ (Signature with date of IEC administrative staff) _____

Note: Information not relevant to a particular SAE should be marked with NA